KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Asset Writedowns and Impairment (2022 - 2024)

Historic Asset Writedowns and Impairment for Ginkgo Bioworks Holdings (DNA) over the last 3 years, with Q2 2024 value amounting to $47.9 million.

  • Ginkgo Bioworks Holdings' Asset Writedowns and Impairment rose 43169.65% to $47.9 million in Q2 2024 from the same period last year, while for Sep 2025 it was $47.9 million, marking a year-over-year decrease of 7013.75%. This contributed to the annual value of $4.8 million for FY2024, which is 9602.73% down from last year.
  • As of Q2 2024, Ginkgo Bioworks Holdings' Asset Writedowns and Impairment stood at $47.9 million, which was up 43169.65% from $112.4 million recorded in Q3 2023.
  • Ginkgo Bioworks Holdings' Asset Writedowns and Impairment's 5-year high stood at $112.4 million during Q3 2023, with a 5-year trough of -$10.1 million in Q4 2022.
  • For the 3-year period, Ginkgo Bioworks Holdings' Asset Writedowns and Impairment averaged around $39.8 million, with its median value being $28.4 million (2023).
  • The largest annual percentage gain for Ginkgo Bioworks Holdings' Asset Writedowns and Impairment in the last 5 years was 43169.65% (2024), contrasted with its biggest fall of 43169.65% (2024).
  • Quarter analysis of 3 years shows Ginkgo Bioworks Holdings' Asset Writedowns and Impairment stood at -$10.1 million in 2022, then surged by 1212.9% to $112.4 million in 2023, then plummeted by 57.42% to $47.9 million in 2024.
  • Its last three reported values are $47.9 million in Q2 2024, $112.4 million for Q3 2023, and $9.0 million during Q2 2023.